Breakthrough KRAS-Targeting Drug Daraxonrasib Nearly Doubles Pancreatic Cancer Survival in Groundbreaking Trial
Scientists have achieved a breakthrough in targeting the KRAS mutation, a long-standing “undruggable” driver of pancreatic cancer, with a new drug that nearly doubles survival in advanced cases. How a ... Read More